The FDA also requested Novavax conduct a phase 4 study in patients aged 50 to 64 years without high-risk conditions for severe COVID-19.

Novavax received Food and Drug Administration approval for its new, protein-based COVID-19 vaccine, and shares jumped 25% at ...

The FDA grants full approval to Novavax's protein-based COVID-19 vaccine after nearly a two-month delay, albeit with some new ...

After delays, the FDA has greenlit the Novavax COVID vaccine for targeted groups. Learn more about the approval and what it ...

US FDA approves Novavax’s BLA for Covid-19 vaccine, Nuvaxovid: Gaithersburg, Maryland Tuesday, May 20, 2025, 14:00 Hrs [IST] Novavax, Inc. announced that the US Food and Drug Ad ...

In the options pits, NVAX has already seen quadruple the overall options volume it typically sees in an entire session, with ...

US health regulators have given final approval to Novavax's COVID vaccine after an unusual delay and have placed new ...

The vaccine, Nuvaxovid, is the third coronavirus shot to gain full approval, joining vaccines from Pfizer and Moderna. It has ...

Plus: FDA approves COVID-19 vaccine developed in Gaithersburg; Robert Frost student to compete in National Spelling Bee ...

The biotechnology company said the FDA approved the biologics license application for Nuvaxovid to prevent Covid-19 in adults ages 65 and up and individuals ages 12 through 64 who have at least one ...

JN.1, a variant of Omicron BA.2.86, emerged in late 2023 with 30 immune-evasion mutations. It spreads more efficiently due to ...

At long last, Novavax has secured a full FDA approval for its protein-based COVID-19 vaccine, though not in the broad ...